R. E. Millikan

724 citations
13 papers · 595 indexed · h-index 7

Impact in

    • Carcinogens and Genotoxicity Assessment
    • Cancer, Lipids, and Metabolism
    • Drug Transport and Resistance Mechanisms

Papers in

R. E. Millikan

13 papers receiving 588 citations

Peers

R. E. Millikan
Comparison fields: 5 of 73
  • Cancer Research 124
  • Oncology 182
  • Molecular Biology 302
  • Surgery 187
  • Pulmonary and Respiratory Medicine 135
Replace E. E. Holdener with:
E. E. Holdener Switzerland
Jason B. Litten United States
Bernie Fitzharris United Kingdom
M Fukushima Japan
Lisa R. Treviño United States
D Oram United Kingdom
Rangaswamy Govindarajan United States
Frédéric Vallot Belgium
Hussein Khaled Egypt
Myla Lai-Goldman United States
R. E. Millikan relative to E. E. Holdener Switzerland E. E. Holdener's profile →
Citations per field
00.5×10×15×20×
E. E. Holdener · 1×
Citations per year

Countries citing papers authored by R. E. Millikan

Since Specialization
Citations

This map shows the geographic impact of R. E. Millikan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Millikan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Millikan more than expected).

Fields of papers citing papers by R. E. Millikan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. E. Millikan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Millikan. The network helps show where R. E. Millikan may publish in the future.

Co-authors

The 25 scholars most cited alongside R. E. Millikan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with R. E. Millikan Line = papers co-authored together R. E. Millikan links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1 2006230
2 2005131
3 200167
4
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
199766
5 200746
6 200928
7
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.
199819
8 20113
9 20041
10 20041
11 20041
12 20081
13 20041

About R. E. Millikan

R. E. Millikan is a scholar working on Pulmonary and Respiratory Medicine, Statistics and Probability, Cancer Research, Oncology and Nephrology, having authored 13 papers that have together received 595 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Prostate Cancer Diagnosis and Treatment (3 papers), Renal cell carcinoma treatment (3 papers), Cancer Treatment and Pharmacology (2 papers), Protein Degradation and Inhibitors (2 papers), Cancer, Lipids, and Metabolism (2 papers), Renal and related cancers (2 papers) and Bladder and Urothelial Cancer Treatments (2 papers). The work is most often cited by research in Cancer Research (124 citations), Oncology (182 citations), Molecular Biology (302 citations), Surgery (187 citations) and Pulmonary and Respiratory Medicine (135 citations). R. E. Millikan has collaborated with scholars based in United States and Spain. Frequent co-authors include H. Barton Grossman, Xifeng Wu, Colin P. Dinney, Jian Gu, Qing Zhang, Maosheng Huang, Carol J. Etzel, Margaret R. Spitz, Christopher I. Amos and Lance C. Pagliaro. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, The American Journal of Human Genetics, Annals of Oncology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026